The Europe Cervical Cancer Diagnostics and Therapeutics market has been estimated at USD 1079.25 Million in 2022. It is projected to reach USD 1275.63 Million by 2027, at a CAGR of 3.40% during the forecast period from 2022 to 2027.
The growing population and the Increase in prevalence of cervical cancer among women are majorly driving the cervical cancer diagnostics and therapeutics market in Europe. However, as in this region, about 33,000 cases of cervical cancer were diagnosed with 15,000 fatalities, as the coverage of human papillomavirus (HPV) is low in the countries with the most significant prevalence and screening effectiveness varies in European countries. Therefore, increasing prevalence is increasing the demand for cervical cancer diagnostics and therapeutics in the market.
In addition, an increase in the pipeline of cervical cancer screening tests is also driving the market growth of cervical cancer diagnostics and therapeutics. The growing technological advancements for developing innovative and effective diagnostics procedures for treating cervical cancer and raising awareness about disease prevention are likely to propel market growth.
Furthermore, the Increase in investment and fundings from government and non-government firms in research activities for developing effective treatment and prevention methods for cervical cancer is expected to drive the market growth.
However, the Increase in the high costs of the treatment and therapies and the lack of trained and skilled individuals for operating screening tests is limiting the growth rate of the European cervical diagnostics and therapeutics market. Also, the lack of awareness among the people about the pre-diagnosing effects and HPV vaccines in the region also restraints the growth of the market. In addition, the strict government rules and regulations with stringent approval processes make the entry of the product difficult in the market, hampers the growth of the cervical cancer diagnostics and therapeutics market.
This research report on the European cervical cancer diagnostics and therapeutics market has been segmented and sub-segmented into the following categories:
By Diagnostics Test:
Geographically, the European market is estimated to be the second-largest regional market in the global cervical cancer diagnostics and therapeutics market during the forecast period. The growing population and lack of effective and efficient screening programs for treating and detecting pre-cancerous conditions are the leading causes that increase the demand for proper cervical cancer diagnostics and therapeutics. As a result, the countries such as Germany, UK, France, and Italy significantly contribute to the regional market growth.
In this region, the UK accounts for around 3200 new cervical cancer cases every year due to lack of access and proper cervical cancer prevention and control services. But this has seen a significant increase in the market due to the rising awareness about prevention and controlling the spread of cancer. In addition, the presence of various treatments or tests available in the market also contributes to growth in the market.
On the other hand, an increase in initiatives for arranging programs associated with cervical cancer pre- diagnosing benefits and preventive measures, increase in the government and non-government organization investments in research and development activities are also driving the growth of cervical cancer diagnostics and therapeutics in the market.
KEY MARKET PLAYERS:
A few of the promising companies operating in the European cervical cancer diagnostics and therapeutics market profiled in this report are Abbott Diagnostics, Alere, Beckman Coulter, Clinical Genomics, Companion Dx, EDP Biotech, Epigenomics AG, Exact Sciences, Fujirebio, Genomic Tree, Metabiomics, Oncocyte (Biotime), Quest Diagnostics, Randox Laboratories, Siemens Healthcare, and Volition Rx.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]